Sign in
Taking peoplePhase 1/2

Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD)

Key facts

Who runs it
Universidade do Sul de Santa Catarina
Where
Brazil1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
60 people, planned
Started
1 May 2026
Expected to end
18 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Experimental: Full-spectrum CBG oil 30 mg/mL
  • Placebo oil (MCT oil)
Record updated
18 May 2026

Who can take part

Age
12 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Adolescents aged 12 to 17 years
  • Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) confirmed using the SNAP-IV (Swanson, Nolan and Pelham Questionnaire, version IV)
  • History of previous treatment with pharmacological or non-pharmacological interventions without significant improvement of symptoms
  • Absence of severe psychiatric disorders or relevant physical comorbidities
  • Ability of the participant and legal guardian to understand study procedures
  • Provision of written informed consent by the legal guardian and assent by the adolescent

Who cannot take part

  • Use of cannabinoid-based substances (natural or synthetic) within 30 days prior to study initiation
  • History of intolerance or adverse reactions to cannabis-derived compounds (e.g., confusion, paranoia, pruritus, excessive drowsiness, vomiting, diarrhea, or seizures)
  • Presence of severe psychiatric disorder not related to ADHD
  • Moderate to severe cognitive impairment
  • Presence of any significant physical comorbidity
  • Inability or unwillingness to complete study procedures or questionnaires adequately

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Attention-deficit/hyperactivity disorder

This trial is currently available in Brazil.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate the potential effects of full-spectrum cannabigerol (CBG) oil on cognitive and behavioral symptoms in adolescents diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, often associated with impairments in academic, social, and emotional functioning.

Read full original descriptionShow less

This is a randomized, double-blind, placebo-controlled clinical trial with a parallel design. A total of 60 adolescents aged 12 to 17 years, diagnosed with ADHD and with insufficient response to previous treatments, will be enrolled and randomly assigned to either the intervention group or the placebo group.

Participants in the intervention group will receive full-spectrum CBG oil (30 mg/mL), administered sublingually, with individualized dosing determined by the study physician and adjusted through weekly monitoring. The placebo group will receive an inert oil matched in appearance and administration conditions.

The intervention will last for 12 weeks, including in-person clinical assessments at baseline, week 6, and week 12, as well as weekly remote monitoring to assess adherence, safety, and dose adjustments.

Primary outcomes will include changes in ADHD symptom severity measured by the SNAP-IV scale. Secondary outcomes will assess quality of life, emotional symptoms, sleep patterns, and safety profile.

This study aims to contribute to the scientific understanding of cannabinoids as a potential therapeutic option for adolescents with ADHD, a population for which current evidence remains limited.

The 2 groups in the trial

  • Full-spectrum CBG oil 30 mg/mLTreatment being tested

    Participants allocated to this arm will receive sublingual administration of full-spectrum cannabigerol oil for 12 weeks under double-blind conditions. The formulation contains cannabigerol, cannabidiol, and a low concentration of tetrahydrocannabinol. Clinical assessments will be performed at baseline, Week 6, and Week 12, with weekly remote monitoring to evaluate adherence, tolerability, adverse events, and the need for dose adjustments.

    Treatment: Experimental: Full-spectrum CBG oil 30 mg/mL

  • Placebo (MCT oil)Placebo, for comparison

    Participants allocated to this arm will receive sublingual administration of placebo oil for 12 weeks under double-blind conditions. The placebo formulation consists of medium-chain triglyceride (MCT) oil matched to the experimental product in appearance, viscosity, color, and administration schedule. Clinical assessments will be performed at baseline, Week 6, and Week 12, with weekly remote monitoring to evaluate adherence, tolerability, adverse events, and the need for dose adjustments.

    Treatment: Placebo oil (MCT oil)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Potential Effects of Cannabigerol in Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (CAN-ADHD)
Criteria questions
Built from NCT07592390, who can take part
Record updated
18 May 2026